Why the study?
Does a single oral dose of labetalol 200 mg reduce blood pressure and systemic resistance compared to placebo in young and older adults with mild hypertension?
Does a single oral dose of labetalol 200 mg reduce blood pressure and systemic resistance compared to placebo in young and older adults with mild hypertension?
A single 200 mg oral dose of labetalol effectively lowers blood pressure in both young and older patients with mild hypertension primarily by reducing peripheral resistance.
Supports single-dose labetalol for acute BP reduction in mild hypertension; extends efficacy evidence to both young and older adults.
Twenty young (45 years or younger) and 20 older (55 years or older) adult patients with mild hypertension were enrolled in this study to compare the hemodynamic effects of labetalol versus placebo in two age groups. Ten patients in each group were randomly assigned to receive either a single oral dose of labetalol (200 mg) or placebo. Hemodynamic parameters were recorded immediately before and two hours after ingestion. Labetalol was more effective than placebo in significantly lowering systolic blood pressure (-11 versus + 5 mm Hg, -23 versus + 4 mm Hg), diastolic blood pressure (-9 versus + 2 mm Hg, -12 versus + 5 mm Hg), and total systemic resistance (-259 versus + 42 dynes-sec cm-5, -390 versus + 74 dynes-sec cm-5) in young and older hypertensive subjects, respectively. There was no significant changes in heart rate, stroke volume index, or cardiac index in either age group. These data indicate that labetalol lowers blood pressure in young an older hypertensives primarily by reducing peripheral resistance and that the antihypertensive effect may be somewhat greater in older patients.
No takes yet. Share an insight, caveat, or question.
Buell et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: